ATE433115T1 - Timp-2 als ziel/marker des versagens von beta- zellen - Google Patents

Timp-2 als ziel/marker des versagens von beta- zellen

Info

Publication number
ATE433115T1
ATE433115T1 AT05760716T AT05760716T ATE433115T1 AT E433115 T1 ATE433115 T1 AT E433115T1 AT 05760716 T AT05760716 T AT 05760716T AT 05760716 T AT05760716 T AT 05760716T AT E433115 T1 ATE433115 T1 AT E433115T1
Authority
AT
Austria
Prior art keywords
timp
marker
target
cell failure
beta cell
Prior art date
Application number
AT05760716T
Other languages
English (en)
Inventor
Andreas Christ
Stefan Evers
Kurt Krapfenbauer
Elena Sebokova
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE433115T1 publication Critical patent/ATE433115T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05760716T 2004-07-28 2005-07-19 Timp-2 als ziel/marker des versagens von beta- zellen ATE433115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103608 2004-07-28
PCT/EP2005/007853 WO2006010529A1 (en) 2004-07-28 2005-07-19 Timp-2 as target/marker of beta cell failure

Publications (1)

Publication Number Publication Date
ATE433115T1 true ATE433115T1 (de) 2009-06-15

Family

ID=34972635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05760716T ATE433115T1 (de) 2004-07-28 2005-07-19 Timp-2 als ziel/marker des versagens von beta- zellen

Country Status (9)

Country Link
US (1) US20100009462A1 (de)
EP (1) EP1774338B1 (de)
JP (1) JP4562771B2 (de)
CN (1) CN1993619A (de)
AT (1) ATE433115T1 (de)
CA (1) CA2574417C (de)
DE (1) DE602005014778D1 (de)
ES (1) ES2325789T3 (de)
WO (1) WO2006010529A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2681955T3 (es) 2013-01-17 2018-09-17 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
CA2920521A1 (en) * 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US10224053B2 (en) * 2017-03-24 2019-03-05 Hyundai Motor Company Audio signal quality enhancement based on quantitative SNR analysis and adaptive Wiener filtering
WO2018187453A1 (en) * 2017-04-05 2018-10-11 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI223599B (en) * 1999-05-24 2004-11-11 Shionogi & Co Evaluation method of matrix metalloprotease inhibitory activity
US6673623B1 (en) * 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
AUPS282002A0 (en) * 2002-06-06 2002-06-27 Gropep Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
ES2325789T3 (es) 2009-09-17
CA2574417A1 (en) 2006-02-02
WO2006010529A1 (en) 2006-02-02
JP4562771B2 (ja) 2010-10-13
EP1774338A1 (de) 2007-04-18
CA2574417C (en) 2010-09-28
US20100009462A1 (en) 2010-01-14
CN1993619A (zh) 2007-07-04
DE602005014778D1 (de) 2009-07-16
JP2008508502A (ja) 2008-03-21
EP1774338B1 (de) 2009-06-03

Similar Documents

Publication Publication Date Title
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006084195A3 (en) Personal assessment including familial risk analysis for personalized disease prevention plan
WO2009059150A3 (en) Biomarkers for fatty liver disease and methods using the same
EP1547996A4 (de) Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
DK2848938T3 (da) Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
DE602006011896D1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
ATE535612T1 (de) Toxizitätsscreeningverfahren
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
EA200800087A1 (ru) Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа
DK2005162T3 (da) Screeningsmetode
WO2006084101A3 (en) Method and apparatus for determining familial risk of disease
EP1907018A4 (de) Diagnose und prognose von diabetes
WO2007134028A3 (en) Biomarkers for depression and methods using the same
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
WO2011143575A3 (en) smFRET WITH MEMBRANE PROTEINS
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
EP2539709A4 (de) Morbus-alzheimer-spezifische änderungen von proteinkinase-c-epsilon- (pkc-epsilon-)proteinspiegeln
WO2006010533A3 (en) Pancreatic polypeptide as target/marker of beta cell failure
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
DE602005010712D1 (de) Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties